- Home
- DDI vs BCYC Comparison
DDI vs BCYC Comparison
Compare DDI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDI | BCYC |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | South Korea | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.6M | 360.7M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DDI | BCYC |
|---|---|---|
| Price | $8.95 | $5.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $19.00 | $17.56 |
| AVG Volume (30 Days) | 57.3K | ★ 324.1K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.65 | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | $4.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.09 | $4.77 |
| 52 Week High | $11.25 | $9.94 |
Technical Indicators
Market Signals| Indicator | DDI | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 40.20 |
| Support Level | $8.64 | $5.03 |
| Resistance Level | $9.32 | $5.90 |
| Average True Range (ATR) | 0.35 | 0.26 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 40.22 | 32.16 |
Price Performance
Historical ComparisonAbout DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.